Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.
The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.
The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.
Brii Biosciences has not published a global access plan for its product.
Brii Biosciences has not made a commitment to comply with human rights.
The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.
Brii Biosciences has not committed to C-TAP or the MPP.
Brio Biosciences has not committed to not enforcing the exclusive rights of Covid-19 related patents.
Brii Biosciences has not signed an agreement with the ACT Accelerator so far.
Brii Biosciences has partnered with WuXi Biologics for manufacturing. This is dubbed a ‘strategic collaboration’, which grants Brii Bio access to WuXi Biologics’ antibody platform technology. WuXi biologics is then to be the “exclusive development and manufacturing partner of any novel bispecific antibodies discovered from the WuXiBody Platform”.
The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.
No information has been found on this criterion.
Brii Bio’s partnership with WuXi Biologics gives access to ‘the entire antibody platform and technology to discover novel bispecific antibodies’.